Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jiangxi Sanxin Medtec Co.,Ltd. (300453.SZ)
Nanchang, CN
Established in Nanchang, China, in 1997, Jiangxi Sanxin Medtec Co., Ltd. is a medical technology company dedicated to the research, development, manufacturing, sales, and servicing of medical devices. The company operates both domestically and internationally, offering a wide array of products across several key therapeutic categories: Renal Dialysis and Blood Purification: This segment includes advanced centralized dialysate supply systems, hemodialysis water preparation units, and hemodialysis machines. It also provides a variety of consumables such as specialized nursing kits, central venous catheter packs, arteriovenous spikes, HDF accessory tubing, dialysate filters, hemodialysis powders and concentrates, hollow fiber hemodialyzers, sterile blood circuits, and tubing sets for hemodialysis. Infusion and Transfusion Equipment: The company supplies various infusion and transfusion sets, including light-resistant, TPE precise filter, and auto-stop fluid precise filter types, alongside standard transfusion sets, catheter infusion sets, and precise filter light-resistant options. Injection Devices: Its portfolio encompasses diverse syringes, such as insulin, dispenser, sterile, auto-disable, and fixed-dose immunization syringes. This category also features hypodermic needles, innovative needleless injection systems, and pneumatic syringes. Intravenous Catheterization Products: Offerings include various indwelling catheters like straight, Y-type, and closed IV catheters, positive pressure IV catheters, central venous catheter kits, extension tubes with three-way valves, and heparin caps. General Medical Supplies: Additional products include blood microembolus filters, disposable extracorporeal circulation tubing kits, cold cardioplegic solution perfusion apparatus, blood containers, medical-grade surgical masks, disinfectants, and alcohol pads.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.30% | -7.98% | -9.62% | -2.15% | -1.62% | +4.47% | +11.23% | +23.95% | -22.99% | +37.61% | +221.91% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+9.3% ★ Q1'26: +13.4% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%+15.9% Q1'26: +30.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+19.7% Q1'26: -10.6% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+19.9% ★ Q1'26: +21.5% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+25.5% ★ Q1'26: +23.2% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%+0.2% Q1'26: -0.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.47× ★ Q1'26: 0.60× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
311.85M
est: 404.00M (-22.8%)
|
317.77M
est: 404.00M (-21.3%)
|
403.87M
est: 500.00M (-19.2%)
|
531.30M
est: 618.00M (-14.0%)
|
940.39M
est: 1.03B (-8.5%)
|
1.27B
est.
|
1.16B
est: 1.52B (-23.2%)
|
1.30B
est: 1.39B (-6.4%)
|
1.34B
est: 1.39B (-3.8%)
|
1.50B
est: 1.49B (+0.9%)
|
1.64B
est: 1.74B (-5.8%)
|
1.90B
1.90B – 1.90B
+9.0% YoY
|
2.26B
2.26B – 2.26B
+19.0% YoY
|
2.69B
2.69B – 2.69B
+19.1% YoY
|
| EBITDA |
75.61M
est: 94.76M (-20.2%)
|
57.95M
est: 94.76M (-38.9%)
|
70.34M
est: 117.28M (-40.0%)
|
78.99M
est: 144.96M (-45.5%)
|
204.95M
est: 240.94M (-14.9%)
|
298.33M
est.
|
253.00M
est: 355.60M (-28.9%)
|
330.86M
est: 325.81M (+1.5%)
|
291.70M
est: 325.81M (-10.5%)
|
369.13M
est: 359.55M (+2.7%)
|
447.45M
est: 421.21M (+6.2%)
|
458.93M
458.93M – 458.93M
+9.0% YoY
|
545.97M
545.97M – 545.97M
+19.0% YoY
|
650.18M
650.18M – 650.18M
+19.1% YoY
|
| EBIT |
61.89M
est: 72.03M (-14.1%)
|
42.23M
est: 72.03M (-41.4%)
|
49.88M
est: 89.15M (-44.0%)
|
50.04M
est: 110.19M (-54.6%)
|
155.11M
est: 183.15M (-15.3%)
|
226.77M
est.
|
197.45M
est: 270.30M (-27.0%)
|
258.09M
est: 247.65M (+4.2%)
|
228.56M
est: 247.65M (-7.7%)
|
280.02M
est: 274.98M (+1.8%)
|
326.06M
est: 322.14M (+1.2%)
|
350.99M
350.99M – 350.99M
+9.0% YoY
|
417.56M
417.56M – 417.56M
+19.0% YoY
|
497.26M
497.26M – 497.26M
+19.1% YoY
|
| Net Income |
51.88M
est: 52.25M (-0.7%)
|
36.61M
est: 52.25M (-29.9%)
|
42.39M
est: 58.58M (-27.6%)
|
41.15M
est: 96.58M (-57.4%)
|
115.62M
est: 101.33M (+14.1%)
|
139.33M
est.
|
155.91M
est: 204.52M (-23.8%)
|
206.63M
est: 194.29M (+6.4%)
|
184.63M
est: 194.29M (-5.0%)
|
227.40M
est: 243.05M (-6.4%)
|
264.94M
est: 258.56M (+2.5%)
|
315.44M
315.44M – 315.44M
+22.0% YoY
|
377.50M
377.50M – 377.50M
+19.7% YoY
|
455.06M
455.06M – 455.06M
+20.5% YoY
|
| SGA |
52.43M
est: 32.37M (+62.0%)
|
60.89M
est: 32.37M (+88.1%)
|
68.41M
est: 40.06M (+70.8%)
|
101.65M
est: 49.51M (+105.3%)
|
129.66M
est: 82.29M (+57.6%)
|
101.89M
est.
|
158.38M
est: 121.45M (+30.4%)
|
169.71M
est: 111.28M (+52.5%)
|
193.43M
est: 111.28M (+73.8%)
|
192.01M
est: 172.97M (+11.0%)
|
69.31M
est: 202.63M (-65.8%)
|
220.77M
220.77M – 220.77M
+9.0% YoY
|
262.65M
262.65M – 262.65M
+19.0% YoY
|
312.78M
312.78M – 312.78M
+19.1% YoY
|
| EPS |
0.11
est: 0.10 (+7.6%)
|
0.07
est: 0.10 (-27.9%)
|
0.09
est: 0.11 (-24.5%)
|
0.08
est: 0.19 (-56.5%)
|
0.23
est: 0.20 (+16.1%)
|
0.27
est.
|
0.31
est: 0.40 (-22.5%)
|
0.40
est: 0.38 (+5.3%)
|
0.36
est: 0.38 (-5.3%)
|
0.44
est: 0.47 (-6.4%)
|
0.51
est: 0.50 (+2.0%)
|
0.61
0.61 – 0.61
+22.0% YoY
|
0.73
0.73 – 0.73
+19.7% YoY
|
0.88
0.88 – 0.88
+20.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-25 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-22 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-19 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-15 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-13 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-12 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-11 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-08 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-07 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-06 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | VanEck - China New Economy ETF CNEW.AX | 0.87% | 617.4K | 0.95% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bing Rong Liu | Vice President | — | male |
| Ganying Wang | Vice President | — | female |
| Ling Peng | Vice President | — | female |
| Lingli Leng | Vice President | — | female |
| Ming Liu | Vice President, Acting Financial Director, Board Secretary & Non-Independent Director | — | male |
| Nan Mei Shu | Accounting Officer | — | female |
| Zhiping Mao | GM & Non-Independent Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300453.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
